Skip to main content
Premium Trial:

Request an Annual Quote

Rounding Out NimbleGen Workflow, Roche Acquires BioMicro Hyb Station, Mixers


By Justin Petrone

Roche Diagnostics last week announced a deal with Salt Lake City-based BioMicro Systems to buy all of BioMicro's products associated with the Roche NimbleGen microarray workflow.

The acquired assets include instruments that are part of the Roche NimbleGen microarray workflow, such as the 4- and-12-bay NimbleGen Hybridization Systems. Also included in the purchase are array accessories covering mixing hybridization chambers designed for use with NimbleGen arrays. Both product lines were sold separately by BioMicro under its MAUI brand.

Roche Diagnostics will continue to provide global sales, service, and support for all products in the NimbleGen microarray workflows, the firm said.
Roche added that it will transfer the manufacturing capabilities associated with the products to its own in-house facility.

"Acquiring these assets will allow Roche complete control over the production, support, and service of these products to ensure continued timely distribution, full support, and the high level of service our customers have grown to expect from Roche," Andreas Görtz, Roche NimbleGen's vice president of marketing, said in a statement.

NimbleGen originally partnered with BioMicro for custom hybridization for its chips in 2007, before it was acquired by Roche later that year (see BAN 6/24/2008). Roche NimbleGen has since debuted a whole workflow including instrumentation and software for use with its arrays (see BAN 1/6/2009).

BioMicro sells other products, including IGOR, an automated benchtop laboratory assistant capable of automating various laboratory protocols including fluorescent in situ hybridization, whole-mount in situ hybridization, blots, and other slide-based applications.

Financial terms of the agreement between Roche and BioMicro were not released.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.